BRD2 and cancer: The median of total dose of gonadotropins (FSH cumulative dose) used was significantly higher in the cancer patients than in the healthy women (2250 vs. 1425, p < 0.0001), and on the triggering day, the median E2 level was significantly lower in the study group vs. the control group (317.5 vs. 1043.5, p < 0.0001).